Synergism of Immunomodulation and Tumor Ablation

NCT03101475 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

22

Enrollment

NETWORK

Sponsor class

Conditions

Colorectal Cancer
Liver Metastases

Interventions

DRUG: Durvalumab (MEDI4736)
DRUG: Tremelimumab
RADIATION: Sterotactic body radiation therapy (SBRT)
OTHER: Radiofrequency ablation (RFA)

Sponsor

European Organisation for Research and Treatment of Cancer - EORTC